Icosavax Inc

Icosavax — Technical Presentation (May 2023)

29 slides from Icosavax's technical presentation, May 22, 2023

  1. Slide 1: IVX-A12 Phase 1 Topline Interim Data

    The world needs better vaccines. We’re striving to create them. IVX-A12 Phase 1 Topline Interim Data | MAY 22, 2023 Exhibit 99.1

  2. Slide 2: Forward looking statements

    Forward looking statements Statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company’s current beliefs and expectations and include, but are not limited to: the company’s expectati

  3. Slide 3: Agenda

    Agenda Introduction and Key Takeaways Adam Simpson Chief Executive Officer Topline Interim Data Niranjan Kanesa-thasan, M.D. Chief Medical Officer Wrap-up and Q&A Adam Simpson Chief Executive Officer Niranjan Kanesa-thasan, M.D. Chief Medical Officer Tom Russo Chief Financial Officer

  4. Slide 4: Positive IVX-A12 Phase 1 topline interim data readout

    Positive IVX-A12 Phase 1 topline interim data* readout Potential first-in-class combination vaccine candidate displaying prefusion F antigens for both RSV and hMPV Robust immune responses to both RSV and hMPV in this clinical trial of older adult subjects First demonstration of hMPV vaccine immunoge

  5. Slide 5: A vaccine preventing both RSV and hMPV could have significant public health impact

    A vaccine able to prevent both RSV and hMPV could have a significant public health impact in older adults U.S. health and economic burden (older adults) RSV hMPV hospitalizations ~105,000 – 177,000 deaths ~14,000 Economic burden: Estimated at $1.5-3B in direct medical costs for ages 60+ Annual estim

  6. Slide 6: Prefusion F protein was a game changer in RSV vaccine development

    The transition to prefusion F protein was a game changer in RSV vaccine development; IVX-A12 incorporates stabilized prefusion F proteins for each of RSV and hMPV IVX-241 hMPV Prefusion stabilized F protein (PreF) also found to be important antigen with hMPV Development of the hMPV PreF antigen in I

  7. Slide 7: IVX-A12 Phase 1 Topline Interim Data

    IVX-A12 Phase 1 Topline Interim Data

  8. Slide 8: Trial design and interim data

    Interim Data through Day 28 Solicited AEs SAEs, AESIs, MAAEs, Unsolicited AEs Immunogenicity DAYS 0-7 DAYS 0-28 DAYS 0 & 28 RSV-A, RSV-B, hMPV-A, & hMPV-B Virus Microneutralization assay Trial Design: Phase 1 randomized, observer-blinded, placebo-controlled trial to evaluate IVX-A12 administration i

  9. Slide 9: Summary of overall interim safety results

    Summary of overall interim safety results Older Adult Subjects (60-75 years of age) IVX-A12 N=117 n (%) Placebo N=23 n (%) Any serious adverse event (AE) 0 0 Any clinical event of special interest (CESI) 0 0 Any AE leading to death or study discontinuation 0 0 Any grade 4 (life-threatening) AE 0 0 A

  10. Slide 10: Solicited adverse events within 7 days of single dose

    Solicited adverse events within 7 days of single dose, maximal severity IVX-A12 was generally well tolerated – solicited adverse events included mild reactogenicity with systemic AEs similar to placebo. No severe solicited AEs. No Adjuvant 150 µg 225 µg 300 µg + MF59 150 µg 225 µg Placebo Placebo No

  11. Slide 11: Interim immunogenicity data: RSV-A and RSV-B NAb

    GMT (95% CI) No Adjuvant + MF59 75 µg IVX-121 150 µg 225 µg 300 µg 150 µg PBO 225 µg GMT (95% CI) No Adjuvant + MF59 75 µg IVX-121 150 µg 225 µg 300 µg 150 µg PBO 225 µg Day 0 and Day 28 Results Day 28 Day 0 RSV-B Interim immunogenicity data: RSV-A and RSV-B NAb GMT expressed in IU/mL – Viroclinics

  12. Slide 12: Interim immunogenicity data: hMPV-A and hMPV-B NAb

    GMT (95% CI) No Adjuvant + MF59 150 µg 225 µg 300 µg 150 µg PBO 225 µg GMT (95% CI) No Adjuvant + MF59 150 µg 225 µg 300 µg 150 µg PBO 225 µg Interim immunogenicity data: hMPV-A and hMPV-B NAb GMT expressed in assay units/mL – Viroclinics Live NAb Assay Day 0 and Day 28 Results Day 28 Day 0 hMPV-B D

  13. Slide 13: IVX-A12 trial sites and RSV seasonality

    IVX-A12 Trial Sites Subjects Enrolled (%)4 Florida 104 (85%) Other 19 (15%) ~Mar-May ’22: RSV Epidemic Onset3 IVX-A12 Ph 1 trial was run during an atypical RSV epidemic following COVID-19 disruptions, with off-cycle RSV circulation potentially contributing to the high baseline titers Florida RSV Pos

  14. Slide 14: RSV NAb sub-analysis, first baseline tertile

    150 µg 225 µg GMT (95% CI) PBO 300 µg 150 µg 225 µg GMT (95% CI) PBO 300 µg RSV-A and RSV-B NAb pre-specified sub-analysis, 1st baseline tertile GMT expressed in IU/mL; pooled by dose – Viroclinics Live NAb Assay RSV-A First Pooled* Baseline Tertile Subjects with lowest baseline titers (1st tertile)

  15. Slide 15: hMPV NAb sub-analysis, first baseline tertile

    150 µg 225 µg GMT (95% CI) PBO 300 µg 150 µg 225 µg GMT (95% CI) PBO 300 µg hMPV-A and hMPV-B NAb pre-specified sub-analysis, 1st baseline tertile GMT expressed in assay units/mL; pooled by dose – Viroclinics Live NAb Assay hMPV-A First Pooled* Baseline Tertile Subjects with lowest baseline titers (

  16. Slide 16: Wrap-up

    g og ICOSAVAX F5—> Wrap-up

  17. Slide 17: Wrap-up: IVX-A12 advancing to Phase 2

    Applies similar approaches to stabilized prefusion F antigen design of RSV to hMPV Robust D28 immunogenicity against two leading causes of viral pneumonia, RSV and hMPV – demonstrated in Phase 1 trial, supporting advancement to Phase 2 Potential to further reduce hospitalizations and deaths in older

  18. Slide 18: Q&A

    g og ICOSAVAX F5—> Q&A

  19. Slide 19: Appendix

    g og ICOSAVAX F5—> Appendix

  20. Slide 20: Data suggest correlation between hMPV titer levels and symptomatic infection

    Data suggest correlation between hMPV titer levels and symptomatic infection MNA titer: <1024 1024-1448 1449-2353 >2353 1 Left panel – Falsey AR et al., 2010: Evaluation of pre-illness baseline titers of subjects with RT-PCR positive hMPV illness and age and group matched controls with no hMPV illne

  21. Slide 21: Exclusive license to prefusion stabilized F antigen in IVX-241

    Icosavax has exclusively licensed rights to the prefusion stabilized F antigen incorporated into IVX-241 (except for one mRNA license that can be granted) IVX-241 for hMPV: Prefusion stabilized F hMPV antigen Prefusion F Protein Postfusion F Protein Battles et al., 2017 Mas et al., 2016 Similar to R

  22. Slide 22: 2022-2023 RSV season more severe with earlier onset

    The 2022-2023 RSV season was more severe and had an earlier onset than pre-pandemic RSV seasons Cumulative U.S. RSV-Associated hospitalizations, ages ≥652 Season Rate per 100,000 2022-2023 66.4 2021-2022 24.5 2020-2021 0.3 2019-2020 45.1 2018-2019 38.7 U.S. Rates of RSV-Associated Hospitalizations,

  23. Slide 23: IVX-A12 targets two common causes of pneumonia in adults

    Our lead candidate IVX-A12 targets two common causes of pneumonia in adults: RSV and hMPV Bacterial Viral Challenging to vaccinate (100s of strains) Approved vaccines exist ~$8B in sales Approved vaccines exist ~$7B in sales Icosavax lead candidate IVX-A12 Respiratory vaccines are an emerging market

  24. Slide 24: Combination vaccine candidate with VLPs incorporating prefusion F proteins

    We are targeting RSV and hMPV in a combination vaccine candidate with VLPs incorporating prefusion-stabilized F proteins from RSV and hMPV viruses RSV Found in 11% of US adults hospitalized for pneumonia where pathogen detected 17% likelihood of ICU admission, 4% likelihood of death Symptoms: Cough,

  25. Slide 25: Preclinical proof of concept against both viral causes of pneumonia

    IVX-A12: Preclinical proof of concept of protection achieved against BOTH viral causes of pneumonia Control (challenge) IVX-A12 Control (no challenge) IVX-121 IVX-A12 IVX-241 Control (challenge) IVX-A12 Control (no challenge) IVX-241 IVX-A12 IVX-121 RSV/A hMPV/A RSV/A hMPV/A Lung viral titers Neutra

  26. Slide 26: RSV / hMPV seasonality suggests benefit of durable combination vaccine

    RSV / hMPV seasonality patterns suggest additional potential benefit of a durable combination vaccine RSV / hMPV seasonality RSV hMPV In most regions, RSV and hMPV show high but not completely overlapping seasonality Data shown for Belgium; other regions (e.g., U.S.) show similar trends RSV tends to

  27. Slide 27: IVX-A12 clinical development plan

    Safety and immunogenicity of bivalent (RSV/hMPV) formulations Healthy older adults (N = 140) Constant RSV dosage (75 µg) + multiple hMPV dosage levels (75, 150, 225 µg) Single dose +/- adjuvant (MF59®) Duration follow-up planned to one year Phase 2b hMPV Human challenge Phase 1 (in progress) Phase 2

  28. Slide 28: Older adult RSV and/or hMPV pipeline candidates

    IVX-A12 is a potential first in class vaccine targeting both RSV and hMPV in the same formulation PRECLINICAL PHASE 1 PHASE 2 PHASE 3 / REGISTRATION VLP Recombinant Vector Bavarian Nordic MVA RSV-F Most technologically competitive w/ Icosavax Nucleic Acid RSV-F + hMPV RSV-F* Protein / Subunit / Solu

  29. Slide 29: Multiple near-term value inflection points

    Novel VLP technology with multiple near-term value inflection points Candidate Indication IVX-A12 RSV/hMPV hMPV candidate selection IND submission Phase 1 initiation FDA Fast Track designation Phase 1 topline interim data Phase 2 initiation [mid ’23] IVX-121 RSV Ph 1/1b topline interim data Phase 1/

Icosavax — Technical Presentation (May 2023) on 6ix